Health TrialsbyHealthPanel

CytOSorb TreatMent Of Critically Ill PatientS Registry

ConditionsSeptic ShockAcute Respiratory Distress SyndromeTraumaRhabdomyolysisCardiogenic ShockPancreatitisAcute on Chronic Liver FailureAcute Liver FailureBurnsChimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)Extracorporeal Life SupportPostoperative EndocarditisHemophagocytic LymphohistiocytosesLiver Transplant; ComplicationsInfectious DiseasePostoperative Vasoplegic SyndromeDrug OverdoseSepsis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCytoSorbents, Inc

About this trial

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Planned OR actual CytoSorb® 300 mL device utilization

Informed consent for prospective registry participation

Disqualifiers

Use of the CytoSorb® 300 mL device for antithrombotic removal only

Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only

The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Trial population

Critically ill patients receiving CytoSorb therapy

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • CytoSorb

    Device

    Sorbent hemoperfusion system

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

ICU mortality

Time frame
Through ICU discharge or date of death, whichever comes first [on average 7 days]
2

In-hospital mortality

Time frame
Through hospital discharge or date of death, whichever comes first [on average 14 days]

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

CytoSorbents, Inc

Lead sponsor

Source ClinicalTrials.gov
Apply now